Sun Pharma’s Q4FY22 Quarter Results
Sun Pharma’s net revenues grew 11% YoY in Q4FY22.
- 30 May 2022
- Sun Pharma’s consolidated revenues for the quarter ended March (Q4FY22) were down 7% quarter-on-quarter (QoQ). On a year-on-year (YoY) basis, it witnessed a growth of 11%.
- Its expenses for the quarter were down 2% QoQ and up 9% YoY
- The company reported a net loss of Rs 2,277 crore in Q4FY22 as against a net profit of Rs 894 crore in Q4FY21.
Sun Pharma’s Financial Statements for Q4FY22:
| (Rs, crores) | Q4FY21 | Q3FY22 | Q4FY22 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 8,634 | 10,296 | 9,560 | -7% | 11% |
Total Expenses | 7,058 | 7,829 | 7,700 | -2% | 9% |
Profit before tax | 903 | 2,466 | -2,076 | - | - |
Tax | 55 | 335 | 147 | -56% | 167 |
Profit after tax | 894 | 2,059 | -2,277 | - | - |
Earnings per share | 3.7 | 8.6 | - |
Data Source: BSE, Company announcements
Want to keep a tab on Indian listed companies? Open an account and get daily stock research updates from Kotak Securities.
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Open Demat Account
